Debate for a new R&D model must start now
This article was originally published in Scrip
The current model for drug development is industry's biggest problem, says Richard Barker director general of the Association of the British Pharmaceutical Industry and vice-chair of the UK Clinical Research Consortium.
You may also be interested in...
Performance-based managed entry agreements need to be made more effective, but this can only happen if countries relax their stance on confidentiality and share information on MEAs amongst themselves, says a working paper from the OECD.
The Netherlands will secure lower medicine prices by referencing Norway instead of Germany to set maximum prices.
Luxembourg’s new regulator will work to attract investment and improve public health as well as tackle the growing problem of drug shortages.